PhaseRx Inc (PZRX) Posts Earnings Results, Beats Expectations By $0.07 EPS

PhaseRx Inc (NASDAQ:PZRX) posted its earnings results on Monday. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.07.

PhaseRx (NASDAQ:PZRX) opened at 1.486 on Tuesday. The firm’s market capitalization is $17.37 million. The stock’s 50 day moving average price is $1.60 and its 200 day moving average price is $1.71. PhaseRx has a 52-week low of $0.96 and a 52-week high of $5.77.

ILLEGAL ACTIVITY NOTICE: “PhaseRx Inc (PZRX) Posts Earnings Results, Beats Expectations By $0.07 EPS” was first reported by Mideast Time and is owned by of Mideast Time. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.mideasttime.com/phaserx-inc-pzrx-posts-earnings-results-beats-expectations-by-0-07-eps/1590345.html.

PhaseRx Company Profile

PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood.

5 Day Chart for NASDAQ:PZRX

Receive News & Ratings for PhaseRx Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseRx Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.